Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Panitumumab; Drug: Pemetrexed; Drug: Cisplatin
Sponsors: WiSP Wissenschaftlicher Service Pharma GmbH; Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Not yet recruiting - verified March 2010
Conditions: Breast Cancer; Lung Cancer; Renal Cancer; Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer Stage IV
Interventions: Drug: SAR240550 (BSI-201); Drug: gemcitabine; Drug: cisplatin
Sponsor: Sanofi-Aventis
Not yet recruiting - verified March 2010
Condition: Carcinoma, Non Small Cell Lung
Intervention: Drug: Pemetrexed/Cisplatin
Sponsor: Spanish Lung Cancer Group
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBW 2992; Drug: Investigator´s choice of chemotherapy
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus BSI-201
Sponsors: BiPar Sciences; Sanofi-Aventis
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Intervention:
Sponsor: AstraZeneca
Not yet recruiting - verified March 2010
Condition: Lung Cancer
Intervention: Other: VB software
Sponsors: VU University Medical Center; Philips Healthcare
Not yet recruiting - verified February 2010
Conditions: Bone Cancer; Bone Metastases; Pain
Intervention: Device: ExAblate 2100
Sponsor: InSightec
Not yet recruiting - verified March 2010
Condition: Stage IIIA Non-small Cell Lung Cancer
Interventions: Radiation: proton beam radiation therapy; Drug: cisplatin; Drug: etoposide; Procedure: therapeutic conventional surgery
Sponsor: Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2010
Conditions: Head and Neck Cancer; Lung Cancer; Liver Cancer; Rectal Cancer; Cervical Cancer
Intervention: Drug: [F 18]HX4
Sponsor: Siemens Molecular Imaging
Recruiting - verified February 2010
Conditions: Non-small Cell Lung Cancer; EGFR Mutations
Intervention: Drug: BIBW 2992
Sponsors: Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified February 2010
Condition: Small Cell Lung Cancer
Intervention: Biological: HLA-A*2402-restricted CDCA1 and KIF20A peptides
Sponsors: Shiga University; Human Genome Center, Institute of Medical Science, University of Tokyo
Not yet recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Intervention: Biological: HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides
Sponsors: Shiga University; Human Genome Center, Institute of Medical Science, University of Tokyo
Not yet recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Intervention: Biological: HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides
Sponsors: Shiga University; Human Genome Center, Institute of Medical Science, University of Tokyo
Not yet recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: RO4929097; Drug: RO4929097
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Carcinoma, Non-Small-Cell Lung; Lung Cancer
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Paclitaxel; Drug: Carboplatin; Drug: Bevacizumab
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Non Small Cell Lung Cancer
Intervention:
Sponsor: AstraZeneca
Recruiting - verified February 2010
Condition: Non-Small-Cell Lung Cancer
Intervention: Drug: ARQ 197 and Erlotinib
Sponsor: Kyowa Hakko Kirin Company, Limited
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: gemcitabine; Drug: gemcitabine; Drug: cisplatin
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified February 2010
Condition: Small Cell Lung Cancer
Intervention: Drug: taxol plus everolimus
Sponsor: Samsung Medical Center
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Intervention: Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Small Cell Lung Cancer
Intervention: Drug: ETOPOSIDE INJECTION
Sponsor: Medicine Invention Design, Inc
Not yet recruiting - verified February 2010
Conditions: Metastatic Non Small Cell Lung Cancer; Metastatic Breast Cancer
Interventions: Drug: Pazopanib; Drug: Vinorelbine
Sponsors: Northwestern University; GlaxoSmithKline
Recruiting - verified February 2010
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Procedure: Endobronchial ultrasound (EBUS); Procedure: Mediastinoscopy
Sponsor: Samsung Medical Center
Not yet recruiting - verified March 2010
Conditions: Non-small Cell Lung Cancer; Adenocarcinoma
Interventions: Drug: SS1 (dsFv) PE38; Drug: Paclitaxel; Drug: Carboplatin; Drug: Bevacizumab
Sponsor: National Cancer Institute (NCI)
Recruiting - verified December 2009
Conditions: Ovarian Cancer; Non Small Cell Lung Cancer; Prostate Cancer; Colorectal Cancer; Gastric Cancer; Esophageal Cancer; Cancer of Head and Neck
Intervention: Drug: LY2523355
Sponsor: Eli Lilly and Company
Not yet recruiting - verified March 2010
Conditions: Advanced Nonhematological Malignancies; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Head and Neck Squamous Cell Carcinoma; Gastroesophageal Adenocarcinoma
Intervention: Drug: MLN8237
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: celecoxib; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Not yet recruiting - verified December 2009
Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Lung Cancer; Respiratory Tract Neoplasms; Advanced Solid Tumor
Interventions: Biological: SCH 900105; Drug: Gefitinib
Sponsors: Schering-Plough; AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2010
Conditions: Pancreatic Cancer; Liver Cancer; Lung Cancer
Intervention: Procedure: MR Imaging
Sponsors: Stanford University; American Association of Physicists in Medicine
Recruiting - verified February 2010
Condition: Extensive-Stage Small Cell Lung Cancer
Interventions: Drug: Amrubicin; Drug: Carboplatin; Drug: Pegfilgrastim
Sponsors: Sarah Cannon Research Institute; Celgene Corporation
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pazopanib; Drug: Erlotinib
Sponsors: Sarah Cannon Research Institute; GlaxoSmithKline; OSI Pharmaceuticals
Recruiting - verified March 2010
Condition: Small Cell Lung Cancer
Intervention: Drug: LY2523355
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Biological: Seneca Valley virus-001; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Intervention: Drug: STA 9090
Sponsor: Synta Pharmaceuticals Corp.
Recruiting - verified February 2010
Condition: Lung Cancer, Stage IIIb or IV
Intervention: Other: CHESS website for lung cancer patient + internet access if needed
Sponsors: University of Wisconsin, Madison; Harry Gray Cancer Center Hartford Hospial; M.D. Anderson Cancer Center; University of Illinois; University of Wisconsin Carbone Cancer Center
Recruiting - verified March 2010
Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: PF-00299804; Genetic: gene expression analysis; Genetic: mutation analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: MM-121 + erlotinib
Sponsor: Merrimack Pharmaceuticals
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: CS-1008; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBW 2992; Drug: Sirolimus (rapamycin)
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: cetuximab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Intervention: Drug: gefitinib
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Recruiting - verified February 2010
Condition: Lung Cancer
Intervention: Drug: bendamustine hydrochloride
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Biological: IMC-11F8
Sponsors: ImClone LLC; Parexel; PPD; Medidata; Laboratory Corporation of America; University of Colorado, Denver; Fisher Clinical Services; ICON Medical Imaging
Recruiting - verified February 2010
Condition: Non Small Cell Lung Cancer
Interventions: Biological: Necitumumab (IMC-11F8); Drug: Gemcitabine; Drug: Cisplatin
Sponsors: ImClone LLC; Parexel; PPD; Medidata; Laboratory Corporation of America; University of Colorado, Denver; Fisher Clinical Services; ICON Medical Imaging
Recruiting - verified February 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBF1120; Drug: Pemetrexed
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Small Cell Lung Carcinoma
Interventions: Drug: Chemotherapy + figitumumab; Drug: Chemotherapy
Sponsor: Pfizer
Not yet recruiting - verified March 2010
Conditions: Rectal Cancer; Breast Cancer; Lung Cancer
Intervention:
Sponsors: Dana-Farber Cancer Institute; American Society of Clinical Oncology
Recruiting - verified March 2010
Conditions: Colorectal Neoplasms; Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Sarcoma
Interventions: Drug: figitumumab; Drug: pegvisomant
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Genetic: EGFR Mutation Test; Genetic: Ki-67 protein expression
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Procedure: Mediastinoscopy/thoracoscopy; Procedure: EBUS/EUS
Sponsors: Mayo Clinic; Medical University of South Carolina
Recruiting - verified March 2010
Conditions: Kidney Cancer; Head and Neck Cancer; Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Esophageal Cancer; Gliomas
Intervention: Drug: 177Lu-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: Erlotinib; Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: pemetrexed; Drug: cisplatin
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Intervention:
Sponsors: AstraZeneca; Laboratorio Progenetica
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Condition: Colorectal Cancer
Intervention: Biological: Adaptive autologous cell immunotherapy
Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting - verified September 2009
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Interventions: Drug: BIBW 2992; Drug: BIBW 2992; Drug: Cisplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pemetrexed
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: gemcitabine; Drug: gemcitabine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Advanced Non-Small Cell Lung Cancer; Postmenopausal Women
Interventions: Drug: fulvestrant (Faslodex); Drug: anastrozole (Arimidex); Drug: Bevacizumab (Avastin); Drug: Best standard of care
Sponsor: University of Pittsburgh
Not yet recruiting - verified February 2010
Conditions: Solid Tumors; Cancer
Interventions: Drug: XL184; Drug: Placebo; Drug: XL184
Sponsor: Exelixis
Recruiting - verified February 2010
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Small Cell Lung Carcinoma; Malignant Epithelial Neoplasms
Interventions: Drug: (Belinostat) (PDX101); Drug: Cisplatin; Drug: Etoposide
Sponsor: National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: FDG-PET; Drug: Pemetrexed; Drug: Sirolimus
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Pemetrexed and temsirolimus
Sponsor: Washington University School of Medicine
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Biological: IMC-3G3; Drug: Paclitaxel; Drug: carboplatin
Sponsor: ImClone LLC
Recruiting - verified March 2010
Condition: Small Cell Lung Carcinoma
Interventions: Drug: BMS-833923; Drug: Carboplatin; Drug: Etoposide
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2010
Conditions: Pulmonary Nodule; Pulmonary Mass
Intervention: Procedure: TBNA + transbronchial lung biopsy + bronchial washing
Sponsor: Maggiore Bellaria Hospital, Bologna
Recruiting - verified February 2010
Conditions: Neoplasms; Pulmonary Disease, Chronic Obstructive; Heart Failure; Renal Disease
Interventions: Other: Outlook Attention Control; Other: Outlook Intervention
Sponsors: Duke University; National Institute of Nursing Research (NINR)
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-751,971; Drug: Cisplatin; Drug: Gemcitabine; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: Pfizer
Not yet recruiting - verified March 2010
Condition: Lung Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Bevacizumab; Drug: Carboplatin
Sponsors: Sarah Cannon Research Institute; Genentech
Recruiting - verified January 2010
Conditions: Lung Cancer; Metastatic Cancer
Interventions: Procedure: central lymph node dissection; Procedure: computed tomography; Procedure: cryosurgery; Procedure: positron emission tomography; Procedure: regional lymph node dissection; Procedure: therapeutic conventional surgery
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified August 2009
Condition: Non Small Cell Lung Cancer
Interventions: Drug: AZD6244; Drug: docetaxel; Drug: Placebo
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Cancer
Interventions: Other: immunological diagnostic method; Other: physiologic testing
Sponsors: Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified June 2009
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Docetaxel and cisplatin; Radiation: Docetaxel and cisplatin Plus Hypofractionated Radiotherapy
Sponsor: University of Chicago
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Docetaxel-Carboplatin
Sponsors: Maestro Clinical, Inc.; Sanofi-Aventis
Recruiting - verified February 2010
Conditions: Breast Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Small Cell Lung Cancer
Intervention:
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Pulmonary Fibrosis; Breast Cancer
Interventions: Drug: Tamoxifen; Radiation: Radiotherapy
Sponsors: Tata Memorial Hospital; Indian Council of Medical Research
Recruiting - verified May 2009
Conditions: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; Lung Cancer, Non-Small Cell
Interventions: Drug: pazopanib and pemetrexed; Drug: pemetrexed and cisplatin
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Biological: Cetuximab; Drug: Gemcitabine; Drug: Carboplatin; Biological: IMC-A12; Drug: Cisplatin
Sponsor: ImClone LLC
Recruiting - verified February 2010
Condition: Lung Cancer
Intervention: Drug: Hydralazine and Valproic Acid
Sponsor: New Mexico Cancer Care Alliance
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate; Procedure: standard follow-up care
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Biological: REOLYSIN®; Drug: Carboplatin; Drug: Paclitaxel
Sponsor: Oncolytics Biotech
Recruiting - verified March 2010
Conditions: Non-small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: erlotinib HCl; Drug: pertuzumab
Sponsors: Genentech; Roche Pharma AG
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: erlotinib HCl; Drug: MetMAb; Drug: placebo
Sponsor: Genentech
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab placebo (ie saline solution)
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: BIBF 1120 + docetaxel
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Lung Cancer; Head and Neck Cancer
Intervention: Drug: [F-18]FLT
Sponsor: Siemens Molecular Imaging
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Radiation: CyberKnife Stereotactic Radiotherapy; Procedure: Surgery
Sponsors: Accuray Incorporated; M.D. Anderson Cancer Center
Recruiting - verified March 2010
Conditions: Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms
Intervention: Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Ixabepilone; Drug: Cisplatin; Drug: Ixabepilone; Drug: Cisplatin
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Brain Metastases
Interventions: Drug: Vorinostat; Radiation: Radiation Therapy
Sponsors: Thomas Jefferson University; Merck
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: aflibercept; Drug: topotecan hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Cetuximab; Drug: Paclitaxel; Drug: Carboplatin; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: Accelerated Community Oncology Research Network; ImClone LLC; Advanced Clinical Trial Solutions, LLC
Recruiting - verified February 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BI 6727; Drug: BI 6727; Drug: pemetrexed; Drug: pemetrexed
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: deforolimus; Drug: Comparator: Blinded Ridaforolimus; Drug: Comparator: Blinded Placebo
Sponsors: Merck; Ariad Pharmaceuticals
Recruiting - verified March 2010
Condition: Carcinoma, Non-small Cell
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Advanced Squamous Non-Small Cell Lung Cancer
Interventions: Biological: AMG 479; Biological: AMG 479; Drug: Carboplatin; Biological: AMG 479; Drug: Paclitaxel
Sponsor: Amgen
Recruiting - verified February 2010
Condition: Metastatic Non-small Cell Lung Cancer
Interventions: Drug: CS7017 tablets; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: Folic Acid; Drug: BIBF1120 placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBF 1120 plus docetaxel; Drug: placebo plus docetaxel
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: pemetrexed disodium; Genetic: gene expression analysis; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Procedure: quality-of-life assessment
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cediranib maleate; Drug: paclitaxel; Other: placebo
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: BiBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Other: active surveillance
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Placebo; Drug: Pemetrexed; Other: Best Supportive Care
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Conditions: Lung Cancer; Precancerous Condition
Interventions: Dietary Supplement: inositol; Other: placebo
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified August 2009
Conditions: Lung Cancer; Small Cell Lung Cancer; Solid Tumors; Extensive-Stage Small Cell Lung Cancer
Interventions: Drug: AMG 102 in combination with Cisplatin/Etopiside; Drug: AMG 479 in combination with Carboplatin/Etopiside; Drug: AMG 102 in combination with Carboplatin/Etopiside; Drug: AMG 479 in combination with Cisplatin/Etopiside
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Cancer; Non-small Cell Lung Cancer
Interventions: Drug: XL765; Drug: erlotinib
Sponsor: Exelixis
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Other: clinical observation; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: axitinib; Drug: axitinib; Drug: chemotherapy; Drug: axitinib; Drug: chemotherapy
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: Placebo; Drug: RG1507; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: BMS-690514; Drug: Erlotinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Lung Cancer
Interventions: Drug: Temozolomide; Drug: Temozolomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Schering-Plough
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: ASA404 in combination with docetaxel; Drug: Placebo in combination with docetaxel
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Biological: IMC-1121B; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: ImClone LLC
Recruiting - verified February 2010
Condition: Carcinoma, Non-Small-Cell Lung (NSCLC)
Intervention: Drug: AG-013736
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Radiation: Radiation Therapy
Sponsors: Hoosier Oncology Group; Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung
Interventions: Drug: SCH 727965; Drug: Capecitabine; Drug: Erlotinib
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Renal Cell Carcinoma; Non-small Cell Lung Cancer; Malignant Melanoma; Epithelial Ovarian Cancer; Colorectal Adenocarcinoma
Intervention: Biological: MDX-1105
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Conditions: Metastatic Castration-resistant Prostrate Cancer (mCRPC); Renal Cell Carcinoma (RCC); Malignant Melanoma (MEL); Non-small Cell Lung Cancer (NSCLC)
Intervention: Biological: MDX-1106
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Advanced/Metastatic Non-Small Cell Lung Cancer
Interventions: Drug: Ixabepilone + Carboplatin; Drug: Paclitaxel + Carboplatin
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Osteosarcoma
Interventions: Drug: AZD0530; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration; AstraZeneca
Recruiting - verified February 2010
Conditions: Carcinoma, Non-small Cell; Neoplasm Metastasis
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBW 2992 MA2; Drug: BIBW 2992 QD
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Talactoferrin; Drug: Placebo
Sponsor: Agennix
Recruiting - verified March 2010
Conditions: Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer; Prostate Cancer; Sarcoma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Drug: sorafenib tosylate
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Locally Advanced Non-Small Cell Lung Cancer; NSCLC
Intervention: Drug: Paclitaxel, Carboplatin and Bevacizumab,Erlotinib
Sponsor: Radboud University
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: gemcitabine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: bevacizumab [Avastin]; Drug: Carboplatin-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBW2992; Drug: BIBW2992 + paclitaxel
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: pemetrexed disodium; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Lung Cancer
Intervention: Drug: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)
Sponsors: Memorial Sloan-Kettering Cancer Center; Johns Hopkins University; Sanofi-Aventis
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: pemetrexed disodium
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Advanced Cancer; Chronic Obstructive Pulmonary Disease (COPD); Restrictive Lung Disease; Congestive Heart Failure; End Stage Liver Disease
Intervention: Behavioral: Training Program Intervention
Sponsors: University of Washington; National Institute of Nursing Research (NINR)
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: Amrubicin Hydrochloride; Drug: Etoposide-Cisplatin combined chemotherapy
Sponsor: Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified March 2010
Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Large Cell; Carcinoma, Squamous Cell
Intervention: Drug: Temozolomide
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: montelukast sodium; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsor: National Cancer Institute (NCI)
Recruiting - verified August 2008
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Irinotecan; Drug: Cisplatin; Drug: Pemetrexed
Sponsors: Hellenic Oncology Research Group; University Hospital of Crete
Recruiting - verified March 2010
Condition: Small Cell Lung Cancer
Interventions: Drug: Cisplatin; Drug: Etoposide; Drug: Placebo; Drug: Cisplatin; Drug: Etoposide; Drug: ZD6474
Sponsors: Hoosier Oncology Group; AstraZeneca
Recruiting - verified February 2010
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Carboplatin, Pemetrexed and Bevacizumab
Sponsors: Christiana Care Health Services; Eli Lilly and Company
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Intervention: Drug: recombinant human endostatin
Sponsors: Chinese Academy of Sciences; Chinese Academy of Medical Sciences; Shanghai Jiao Tong University School of Medicine; Beijing Chao Yang Hospital
Recruiting - verified March 2009
Conditions: Lymphedema; Musculoskeletal Complications; Radiation Fibrosis; Radiation Toxicity; Sarcoma
Interventions: Drug: chemotherapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Procedure: conventional surgery; Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma, Non Small Cell Lung
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Non-Small-Cell Lung Cancer
Interventions: Drug: Drug: pemetrexed; Drug: Drug: erlotinib
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Carcinoma, Non Small Cell Lung
Interventions: Drug: PF-00299804; Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Gastric Cancer
Intervention: Drug: Docetaxel plus lonafarnib
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Lung Cancer; Radiation Toxicity
Interventions: Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: BAY 43-9006; Drug: Paclitaxel; Drug: Carboplatin; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; Bayer
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008
Condition: Non-small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Avastin; Drug: Standard platinum-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Esophageal Cancer; Lung Cancer
Interventions: Procedure: 4D CT scans; Procedure: Lung Function Imaging
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Conditions: Gastrointestinal Cancer; Lung Cancer
Interventions: Drug: Melatonin; Drug: Placebo
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Lung Neoplasms
Intervention: Drug: Pemetrexed
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Tumor Antigen-positive Non-Small Cell Lung Cancer
Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Biological: Placebo Control
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: AMG 706; Drug: placebo
Sponsors: Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: pemetrexed disodium; Drug: sorafenib tosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Cervical Cancer; Prostate Cancer; Colorectal Cancer; Lung Cancer
Interventions: Behavioral: Questionnaire; Behavioral: Patient Navigator (PN)
Sponsors: M.D. Anderson Cancer Center; Centers for Medicare and Medicaid Services
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Intraocular Melanoma; Lung Cancer; Melanoma (Skin); Metastatic Cancer; Neuroblastoma; Ovarian Cancer; Retinoblastoma; Sarcoma; Small Intestine Cancer
Interventions: Other: immunologic technique; Other: pharmacological study; Radiation: iodine I 131 monoclonal antibody 3F8
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified July 2009
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Intervention: Drug: IPI-504
Sponsor: Infinity Pharmaceuticals
Recruiting - verified February 2010
Conditions: Lung Cancer; Adenocarcinoma
Intervention: Drug: sunitinib
Sponsors: Swedish Medical Center; Pfizer
Recruiting - verified March 2010
Condition: Lung Cancer
Intervention: Drug: Bortezomib
Sponsors: University of Massachusetts; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Behavioral: Questionnaire; Behavioral: Telephone Interactive System; Other: Blood Samples
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Small Cell Lung Cancer
Intervention:
Sponsors: Groupe Francais De Pneumo-Cancerologie; Baxter Healthcare Corporation; Amgen
Recruiting - verified March 2010
Condition: Brain Metastases From Non-small Cell Lung Cancer
Intervention: Drug: HYCAMTIN, oral capsules
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
Sponsors: Ontario Clinical Oncology Group (OCOG); Roche Pharma AG
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: azacitidine; Drug: entinostat; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Intervention: Procedure: Endobronchial Ultrasound Guided Transthoracic Needle Biopsy
Sponsor: University Health Network, Toronto
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: topotecan hydrochloride
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified January 2009
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Pain; Prostate Cancer
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: vitamin D; Drug: calcium gluconate; Drug: zoledronic acid; Radiation: samarium Sm 153 lexidronam pentasodium; Radiation: strontium chloride Sr 89
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Lung Cancer; Breast Cancer
Intervention: Drug: Gefitinib
Sponsor: AstraZeneca
Recruiting - verified March 2010
Conditions: Ovarian Cancer; Merkel Cell Carcinoma; SCLC
Intervention: Drug: BB-10901
Sponsor: ImmunoGen, Inc.
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified March 2010
Conditions: Kidney Cancer; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Pulmonary Complications; Sarcoma
Interventions: Biological: etanercept; Drug: methylprednisolone
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsor: Roswell Park Cancer Institute
Recruiting - verified February 2010
Conditions: Lung Diseases; Cancer
Intervention: Drug: Combination Paclitaxel, Carboplatin and Temozolomide
Sponsor: New Mexico Cancer Care Alliance
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Intervention: Procedure: Minimum Dose Computed Tomography (MnDCT) scan
Sponsor: University Health Network, Toronto
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-751,871 + paclitaxel + carboplatin; Drug: paclitaxel + carboplatin; Drug: CP-751,871 + paclitaxel + carboplatin; Drug: CP-751,871 + paclitaxel + carboplatin + erlotinib; Drug: CP-751,871 + paclitaxel + carboplatin + erlotinib
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Hypereosinophilic Syndrome; Systemic Mastocytosis; Chronic Myelomonocytic Leukemia; Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Conditions: Mesothelioma; Lung Cancer
Interventions: Drug: Comparator: Suberoylanilide Hydroxamic Acid (Vorinostat, MK0683); Drug: Comparator: Placebo
Sponsor: Merck
Recruiting - verified March 2010
Condition: Lung Cancer
Intervention: Procedure: radiofrequency ablation
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non-Small-Cell Lung Carcinoma
Intervention: Drug: Celecoxib
Sponsors: Department of Veterans Affairs; University of California, Los Angeles; City of Hope Medical Center
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: cetuximab; Drug: Pemetrexed
Sponsors: Eli Lilly and Company; ImClone LLC
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: bortezomib; Drug: carboplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: isolated perfusion; Drug: melphalan
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Conditions: Cystic Fibrosis; Sarcoidosis; Tuberous Sclerosis; Asthma
Intervention:
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2010
All Categories ... by Medical Condition » ... Cancers » ... Lung Cancer 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
